SEC Company Response from CervoMed Inc. (CRVO) (CIK 0001053691) (CRVO) — Oct 4, 2019
CervoMed Inc. (CRVO) (CIK 0001053691)
Date: Oct. 4, 2019 · CIK: 0001053691 · Accession: 0001437749-19-019717
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-233686
Letter
RE:
dffn20191004_corresp.htm
October 4, 2019
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, DC 20549
Diffusion Pharmaceuticals Inc.
Registration Statement on Form S-1
File No. 333-233686
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Diffusion Pharmaceuticals Inc. (the “Registrant”) hereby respectfully requests, subject to telephone confirmation, that the effectiveness of the above-captioned Registration Statement be accelerated so that it will become effective as of 4:00 p.m. EST on October 8, 2019, or as soon thereafter as practicable, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission (the “Staff”). This request for acceleration is subject, however, to your receiving a telephone call prior to such time from our legal counsel, Dechert LLP, confirming this request. The Registrant hereby authorizes each of David Rosenthal and Curtis Weber of Dechert LLP, counsel to the Registrant, to make such request on its behalf.
Very truly yours,
DIFFUSION PHARMACEUTICALS INC.
Show Raw Text
CORRESP 1 filename1.htm dffn20191004_corresp.htm October 4, 2019 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 RE: Diffusion Pharmaceuticals Inc. Registration Statement on Form S-1 File No. 333-233686 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Diffusion Pharmaceuticals Inc. (the “Registrant”) hereby respectfully requests, subject to telephone confirmation, that the effectiveness of the above-captioned Registration Statement be accelerated so that it will become effective as of 4:00 p.m. EST on October 8, 2019, or as soon thereafter as practicable, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission (the “Staff”). This request for acceleration is subject, however, to your receiving a telephone call prior to such time from our legal counsel, Dechert LLP, confirming this request. The Registrant hereby authorizes each of David Rosenthal and Curtis Weber of Dechert LLP, counsel to the Registrant, to make such request on its behalf. Very truly yours, DIFFUSION PHARMACEUTICALS INC. David G. Kalergis Chief Executive Officer